REFERENCES
1. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat 2017;32:23-46.
3. Kyrochristos ID, Ziogas DE, Roukos DH. Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. Drug Discov Today 2019;24:1281-94.
4. Zhitnyak IY, Bychkov IN, Sukhorukova IV, et al. Effect of BN Nanoparticles Loaded with Doxorubicin on Tumor Cells with Multiple Drug Resistance. ACS Appl Mater Interfaces 2017;9:32498-508.
5. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013;65:1866-79.
6. Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resist Updat 2017;31:15-30.
7. Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, et al. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. IUBMB Life 2020;72:855-71.
8. Lepeltier E, Rijo P, Rizzolio F, et al. Nanomedicine to target multidrug resistant tumors. Drug Resist Updat 2020;52:100704.
9. Kesharwani SS, Kaur S, Tummala H, Sangamwar AT. Overcoming multiple drug resistance in cancer using polymeric micelles. Expert Opin Drug Deliv 2018;15:1127-42.
10. Lee ES, Youn YS. Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation. J Phar Investig 2016;46:305-15.
11. Bhushan B, Khanadeev V, Khlebtsov B, Khlebtsov N, Gopinath P. Impact of albumin based approaches in nanomedicine: Imaging, targeting and drug delivery. Adv Colloid Interface Sci 2017;246:13-39.
12. Kimura K, Yamasaki K, Nishi K. Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique. Cancer Chemother Pharmacol 2019;83:1113-20.
13. Onafuye H, Pieper S, Mulac D, Cinatl J, Wass MN, et al. Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. Beilstein J Nanotechnol 2019;10:1707-15.
14. Kayani Z, Firuzi O, Bordbar AK. Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells. Int J Biol Macromol 2018;107:1835-43.
15. Chen B, Wu C, Zhuo RX, Cheng SX. A self-assembled albumin based multiple drug delivery nanosystem to overcome multidrug resistance. RSC Adv 2015;5:6807-14.
16. England CG, Miller MC, Kuttan A, Trent JO, Frieboes HB. Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J Pharm Biopharm 2015;92:120-9.
17. Beretta GL, Cavalieri F. Engineering nanomedicines to overcome multidrug resistance in cancer therapy. Curr Med Chem 2016;23:3-22.
18. Kunjachan S, Błauż A, Möckel D, et al. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur J Pharm Sci 2012;45:421-8.
19. Salomon JJ, Ehrhardt C. Nanoparticles attenuate P-glycoprotein/MDR1 function in A549 human alveolar epithelial cells. Eur J Pharm Biopharm 2011;77:392-7.
20. El-Awady RA, Hersi F, Al-Tunaiji H, et al. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy. Cancer Biol Ther 2015;16:1056-70.
21. Mohajeri M, Sahebkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review. Crit Rev Oncol Hematol 2018;122:30-51.
22. Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 2014;10:853-8.
23. Caldera F, Argenziano M, Trotta F, et al. Cyclic nigerosyl-1,6-nigerose-based nanosponges: An innovative pH and time-controlled nanocarrier for improving cancer treatment. Carbohydr Polym 2018;194:111-21.
24. Daga M, Ullio C, Argenziano M, et al. GSH-targeted nanosponges increase doxorubicin-induced toxicity “in vitro” and “in vivo” in cancer cells with high antioxidant defenses. Free Radic Biol Med 2016;97:24-37.
25. Argenziano M, Gigliotti CL, Clemente N, et al. Improvement in the anti-tumor efficacy of Doxorubicin nanosponges in in vitro and in mice bearing breast tumor models. Cancers (Basel) 2020;12:162.
26. Zhao N, Woodle MC, Mixson AJ. Advances in delivery systems for doxorubicin. J Nanomed Nanotechnol 2018;9:519.
27. Gonçalves M, Mignani S, Rodrigues J, Tomás H. A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. J Control Release 2020;317:347-74.
28. Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2012;426:193-201.
29. Misra R, Das M, Sahoo BS, Sahoo SK. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation. Int J Pharm 2014;475:372-84.
30. Zhao M, Lei C, Yang Y, et al. Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp. PLoS One 2015;10:e0131429.
31. Vallo S, Köpp R, Michaelis M, et al. Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Oncol Lett 2017;13:4085-92.
32. An FF, Zhang XH. Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics 2017;7:3667-89.
33. Baboci L, Capolla S, Di Cintio F, et al. The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target. J Oncol 2020;2020:4638192.
34. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
